Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Subscribe To Our Newsletter & Stay Updated
